glucagon-like-peptide-1 and Drug-Overdose

Glucagon-like peptide (GLP)-1 analogues such as liraglutide have gained popularity in the treatment of type 2 diabetes over the last years. By mimicking the effects of the native GLP-1, it enhances the glucose-dependent secretion of insulin, suppresses elevated glucagon secretion, increases satiety and slows down gastric emptying. Because of its ways of action it is not likely to cause hypoglycaemia in cases of overdosage. We present a 45-fold overdose of liraglutide (confirmed by P-liraglutide measurements) leading to nausea and vomiting, but no hypoglycaemia and no sign of pancreatitis.

Topics: Adult; Blood Glucose; Drug Overdose; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Nausea; Vomiting

Topics: Accidents; Blood Glucose; Drug Overdose; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Middle Aged; Nausea; Treatment Outcome; Vomiting

Topics: Aged; Drug Overdose; Glucagon-Like Peptide 1; Humans; Liraglutide; Male

We document the first reported case of attempted suicide with the GLP-1 receptor agonist, liraglutide: a 33-year-old Japanese woman with type 2 diabetes reported subcutaneously injected 72 mg of liraglutide. She experienced gastrointestinal symptoms but no hypoglycemia.

Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Overdose; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Receptors, Glucagon; Suicide, Attempted; Treatment Outcome